Celsion Corp. (CLSN) Rating Reiterated by HC Wainwright
Celsion Corp. (NASDAQ:CLSN)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research note issued to investors on Monday.
Separately, Maxim Group reiterated a “buy” rating and set a $4.00 target price on shares of Celsion Corp. in a report on Thursday, September 15th.
Shares of Celsion Corp. (NASDAQ:CLSN) opened at 0.815 on Monday. The company has a 50-day moving average of $1.07 and a 200 day moving average of $1.25. Celsion Corp. has a one year low of $0.78 and a one year high of $2.31. The firm’s market cap is $21.04 million.
Celsion Corp. (NASDAQ:CLSN) last posted its quarterly earnings data on Monday, August 15th. The company reported ($0.19) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.02. Celsion Corp. had a negative net margin of 4,390.50% and a negative return on equity of 139.38%. On average, equities research analysts expect that Celsion Corp. will post ($0.85) EPS for the current fiscal year.
A hedge fund recently raised its stake in Celsion Corp. stock. Sabby Management LLC boosted its position in Celsion Corp. (NASDAQ:CLSN) by 7,986.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,519,365 shares of the company’s stock after buying an additional 1,500,576 shares during the period. Sabby Management LLC owned about 6.48% of Celsion Corp. worth $1,930,000 as of its most recent filing with the SEC. Institutional investors own 15.05% of the company’s stock.
About Celsion Corp.
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Receive News & Stock Ratings for Celsion Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corp. and related stocks with our FREE daily email newsletter.